Drug Profile
Research programme: melanin-concentrating hormone receptor 1 antagonists - Boehringer Ingelheim
Alternative Names: Compound B4Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Class Small molecules
- Mechanism of Action MCHR1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Obesity
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Obesity in Germany
- 05 Jul 2005 Data presented at the 87th Annual Meeting of the Endocrine Society (ENDO-2005) have been added to the Obesity pharmacodynamics section
- 30 Jun 2005 Preclinical trials in Obesity in Germany (unspecified route)